Protein Arginine Methyltransferase 5 (PRMT5) Signaling Suppresses Protein Kinase Cδ- and p38δ-dependent Signaling and Keratinocyte Differentiation

被引:23
|
作者
Kanade, Santosh R. [1 ]
Eckert, Richard L. [1 ,2 ,3 ,4 ]
机构
[1] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Reprod Sci, Baltimore, MD 21201 USA
基金
美国国家卫生研究院;
关键词
HUMAN INVOLUCRIN PROMOTER; HUMAN EPIDERMAL-KERATINOCYTES; DISTAL REGULATORY REGION; GREEN TEA POLYPHENOL; P38 MAP KINASE; GENE-EXPRESSION; CROSS-LINKING; PKC-DELTA; CORNIFIED ENVELOPE; P38-DELTA MAPK;
D O I
10.1074/jbc.M111.331660
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PKC delta is a key regulator of keratinocyte differentiation that activates p38 delta phosphorylation leading to increased differentiation as measured by an increased expression of the structural protein involucrin. Our previous studies suggest that p38 delta exists in association with protein partners. A major goal is to identify these partners and understand their role in regulating keratinocyte differentiation. In this study we use affinity purification and mass spectrometry to identify protein arginine methyltransferase 5 (PRMT5) as part of the p38 delta signaling complex. PRMT5 is an arginine methyltransferase that symmetrically dimethylates arginine residues on target proteins to alter target protein function. We show that PRMT5 knockdown is associated with increased p38 delta phosphorylation, suggesting that PRMT5 impacts the p38 delta signaling complex. At a functional level we show that PRMT5 inhibits the PKC delta- or 12-O-tetradecanoylphorbol- 13-acetate-dependent increase in human involucrin expression, and PRMT5 dimethylates proteins in the p38 delta complex. Moreover, PKC delta expression reduces the PRMT5 level, suggesting that PKC delta activates differentiation in part by reducing PRMT5 level. These studies indicate antagonism between the PKC delta and PRMT5 signaling in control of keratinocyte differentiation.
引用
收藏
页码:7313 / 7323
页数:11
相关论文
共 50 条
  • [41] Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
    Liang, Minrui
    Wang, Lingbiao
    Tian, Xiaolong
    Wang, Kun
    Zhu, Xiaoyi
    Huang, Linlin
    Li, Qing
    Ye, Wenjing
    Chen, Chen
    Yang, Haihua
    Wu, Wanqing
    Chen, Xiangjun
    Zhu, Xiaoxia
    Xue, Yu
    Wan, Weiguo
    Wu, Yanling
    Lu, Liwei
    Wang, Jiucun
    Zou, Hejian
    Ying, Tianlei
    Zhou, Feng
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (09) : 1144 - 1155
  • [42] In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking
    Luo, Lianxiang
    Tan, Huiting
    Liao, Yinglin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (22): : 13180 - 13197
  • [43] GANP suppresses the arginine methyltransferase PRMT5 regulating IL-4-mediated STAT6-signaling to IgE production in B cells
    Igarashi, Hideya
    Kuwahara, Kazuhiko
    Yoshida, Mikoto
    Xing, Yan
    Maeda, Kazuhiko
    Nakajima, Koichi
    Sakaguchi, Nobuo
    MOLECULAR IMMUNOLOGY, 2009, 46 (06) : 1031 - 1041
  • [44] Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the canine model of non-Hodgkin lymphoma
    Renaldo, Kyle A.
    Courtney, Lindsay E.
    Shilo, Konstantin
    Baiocchi, Robert A.
    Kisseberth, William C.
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
    Vlummens, Philip
    Verhulst, Stefaan
    De Veirman, Kim
    Maes, Anke
    Menu, Eline
    Moreaux, Jerome
    De Boussac, Hugues
    Robert, Nicolas
    De Bruyne, Elke
    Hose, Dirk
    Offner, Fritz
    Vanderkerken, Karin
    Maes, Ken
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [46] PRMT5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family
    Rho, J
    Choi, S
    Seong, YR
    Cho, WK
    Kim, SH
    Im, DS
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) : 11393 - 11401
  • [47] First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
    Vieito Villar, M.
    Spreafico, A.
    Moreno, V.
    Brana, I.
    Hernandez, T.
    Razak, A. Abdul
    Wang, J.
    Haddish-Berhane, N.
    Mehta, J.
    Johnson, A.
    Maes, A.
    Haslam, J.
    Mistry, P.
    Kalota, A.
    Lenox, L.
    Infante, J.
    Lorenzi, M.
    Xie, H.
    Lauring, J.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S470 - S470
  • [48] Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor
    Rioux, Nathalie
    Duncan, Kenneth W.
    Lantz, Ronald J.
    Miao, Xiusheng
    Chan-Penebre, Elayne
    Moyer, Mikel P.
    Munchhof, Michael J.
    Copeland, Robert A.
    Chesworth, Richard
    Waters, Nigel J.
    XENOBIOTICA, 2016, 46 (03) : 268 - 277
  • [49] Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
    Sloan, Shelby L.
    Renaldo, Kyle A.
    Long, Mackenzie
    Chung, Ji-Hyun
    Courtney, Lindsay E.
    Shilo, Konstantin
    Youssef, Youssef
    Schlotter, Sarah
    Brown, Fiona
    Klamer, Brett G.
    Zhang, Xiaoli
    Yilmaz, Ayse S.
    Ozer, Hatice G.
    Valli, Victor E.
    Vaddi, Kris
    Scherle, Peggy
    Alinari, Lapo
    Kisseberth, William C.
    Baiocchi, Robert A.
    PLOS ONE, 2021, 16 (05):
  • [50] Efficacy of the protein arginine methyltransferase PRMT5 inhibitor GSK591 in glioma stem-like cells
    Shaw, Vikram
    Piao, Yuji
    Park, Soon Young
    Dong, Jianwen
    Martinez-Ledesma, Emmanuel
    Carrillo, Caroline
    Henry, Verlene
    Ezhilarasan, Ravesanker
    Sulman, Erik
    Balasubramaniyan, Veerakumar
    de Groot, John F.
    CANCER RESEARCH, 2018, 78 (13)